Whan In has exclusive distribution rights for Sanofi's Arava

“Whan In Pharm expands its business focus into areas such as rheumatology beyond its specialization in the CNS.”

On the 10th, Whan In Pharm had signed an exclusive promotion & distribution agreement with Sanofi-Aventis Korea for Arava tablet in Korea.

On the 10th, Whan In Pharm announced that the company signed an exclusive promotion and distribution agreement with Sanofi-Aventis for Arava Tablet, a rheumatoid arthritis treatment containing the active ingredient leflunomide, in Korea.

 

Whan In Pharm is recognized for its business specialization in the central nervous system (CNS) field.

 

Through this agreement, Whan In Pharm plans to expand its business focus into areas beyond the CNS.

 

Arava Tablet is a drug for alleviating rheumatoid arthritis symptoms, active psoriatic arthritis symptoms, and others.

 

The drug is steadily generating sales of around 6 billion won every year.

 

“We are pleased to announce our first partnership in the non-CNS field with Sanofi,” Lee Wonbum, CEO of Whan In Pharm, stated.

 

“We anticipate that our collaboration with Sanofi will drive mutual growth and enhance our market competitiveness in the rheumatology field.

 

“We are thrilled to establish a strategic alliance with Whan In Pharm, a company with a proven track of success in the CNS field.

 

Through this partnership, we anticipate that we will be able to steadily supply Arava, an important treatment for Rheumatoid Arthritis, to patients in need,” Suk Sang Kyu, Foundation Business Unit Head at Sanofi-Aventis Korea stated.